Nobel Laureate David Baltimore presented his findings at the Lou Siminovitch Lecture in Toronto and gave a glimpse of all the recent findings related to the plethora of antibodies that are known to bind to HIV. Many of these have broad specificities and high affinities. It is a fun time for antibody research considering the advances made in deciphering the crystal structure of the viral glycoprotein. Baltimore introduced the work of his lab, particularly that of Alex Balazs, in developing a novel form of therapeutics. Termed "Vectored ImmunoProphylaxis" or VIP, the concept is that of getting the body to make antibodies against the virus. Basically, Baltimore and Balazs engineered an Adeno-associated Virus (AAV) which has a small genome to express the heavy and light chains of their favourite antibody. This could be against HIV, Hepatitis or Malaria. The virus is injected into the muscle of mice where the vector starts expressing the antibody protein. When the mouse is...